Novel cancer therapies targeting key cancer pathways
We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.
OUR COMPANY
Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.
OUR SCIENCE
Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.
LATEST NEWS
| 24/07/2018 | June 2019 Appendix 4C - Quarterly | |
| 11/07/2019 | PTX Initiates Phase 1b Clinical Trial for PTX-100 | |
| 30/05/2019 | Change to Exercise Price of Options | |
| 21/05/2019 | Investor Presentation - May 2019 | |
| 21/05/2019 | Prescient to present at Sydney Conference | |
| 16/05/2019 | Canadian Patent Granted for PTX-200 | |
| 06/05/2019 | Change of Director's Interest Notices x4 |